Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Recruiting

Study of esomeprazole effects on endoscopic sleeve gastroplasty structural integrity in obese patients

Verified siteRegistered drugNo placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial focuses on patients with obesity who undergo a weight loss procedure called endoscopic sleeve gastroplasty (ESG). This is a minimally invasive procedure where the stomach is made smaller using an endoscopic device, helping patients feel full with less food. The study examines how medications called proton pump inhibitors (PPIs) affect the success of this procedure.

The study uses esomeprazole, a type of PPI that reduces stomach acid production. The medication will be given in two different forms: as tablets taken by mouth and as a solution given through an intravenous line. The maximum daily dose is 80 mg, and treatment continues for up to 8 weeks.

The purpose of this study is to determine how well the stomach procedure holds up over time when patients take acid-reducing medications. The research team will monitor patients for up to one year after the procedure to check if the stomach maintains its new shape and size. This information will help doctors understand whether these medications affect the long-term success of the weight loss procedure.

The research process

The trial runs in 5 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Initial procedure

    You will undergo an endoscopic sleeve gastroplasty (ESG), which is a procedure to reduce the size of your stomach

    This procedure is performed for patients with a body mass index (BMI) between 30 to 45 kg/m²

  2. Step 2

    Treatment assignment

    You will be randomly assigned to receive either esomeprazole treatment or no treatment

    If assigned to the treatment group, you will receive esomeprazole through two methods:

    - First by intravenous infusion (directly into your vein)

    - Then by oral administration (taking pills by mouth)

  3. Step 3

    6-month follow-up

    After 6 months, your stomach will be examined to check the condition of the ESG procedure

    The examination will determine if the ESG is intact, partially intact, or open

  4. Step 4

    12-month follow-up

    A final examination will be conducted at 12 months

    This examination will again assess the condition of your ESG procedure

    The study will evaluate how the medication affected the long-term results of your procedure

  5. Step 5

    Study completion

    The study is expected to continue until December 31, 2025

    Your participation will help determine if stomach acid-reducing medication (proton pump inhibitors) affects the success of the ESG procedure

Who can join the trial?

6 criteria

  • You must be between 20 and 65 years old
  • Your Body Mass Index (BMI) must be between 30 and 45 (BMI is a measure of body fat based on height and weight)
  • You must be willing to participate and understand all study procedures and requirements
  • You can be either male or female
  • You must be able to follow all study instructions and attend all required visits
  • You must be able to provide informed consent on your own

Who cannot join the trial?

15 criteria

  • Age below 18 or above 65 years old
  • Pregnancy or breastfeeding
  • Active gastric ulcers (open sores in the stomach lining)
  • Previous stomach or weight loss surgery
  • Uncontrolled diabetes (high blood sugar levels)
  • Severe heart or lung diseases
  • Blood clotting disorders or current use of blood thinners
  • Active substance abuse or addiction
  • Body Mass Index (BMI) below 30 or above 40 (BMI is a measure of body fat based on height and weight)
  • Ongoing treatment with medications that could affect stomach acid production
  • History of gastrointestinal bleeding (bleeding in the digestive system)
  • Current participation in other clinical trials
  • Known allergies to medications used in the study
  • Inability to follow study procedures or attend follow-up visits
  • Serious mental health conditions that could affect participation
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

  • Proton pump inhibitors (PPIs)

    are medications that reduce stomach acid production. They work by blocking the enzyme in the stomach wall that produces acid. These medications are commonly used to treat conditions like acid reflux, heartburn, and stomach ulcers. In this trial, they are being studied to understand how they affect the results of endoscopic sleeve gastroplasty (a weight-loss procedure).

  • Endoscopic sleeve gastroplasty (ESG)

    is not a medication but a minimally invasive weight-loss procedure where the stomach is reduced in size using endoscopic suturing. This procedure helps patients feel full with smaller portions of food. The trial examines how the use of PPIs might impact the durability and effectiveness of these sutures.

What is already known about the treatment

Proton Pump Inhibitors (PPIs) - A class of medications taken orally that work by reducing the production of stomach acid by blocking the proton pump in the cells of the stomach lining. These drugs are widely used in modern medicine for treating various conditions including acid reflux, gastric ulcers, and protecting the stomach during certain medical procedures. PPIs act by irreversibly binding to and deactivating the hydrogen/potassium adenosine triphosphatase enzyme system, which results in profound and long-lasting reduction of stomach acid production. In this clinical trial, PPIs are being studied for their potential effects on endoscopic sleeve gastroplasty, a weight loss procedure, demonstrating their expanding role in bariatric medicine and gastroenterology.

Investigated diseases

Obesity - A chronic medical condition characterized by excessive accumulation of body fat that may impair health. The condition develops when caloric intake consistently exceeds energy expenditure over an extended period. Body fat accumulates gradually, affecting various body systems and functions. The condition can be influenced by genetic factors, lifestyle choices, and environmental conditions. Obesity is typically measured using Body Mass Index (BMI), with a BMI of 30 or higher indicating obesity.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2024-517679-18-00Protocol codeE S G I SEstimated enrolment40 patientsSponsorFondazione Policlinico Universitario Agostino Gemelli IRCCS

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.